Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

ElevateBio

Biotech & Life Sciences · Waltham, United States · Founded 2018 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$2.5–5B
Latest valuation · 2026
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value

Accelerating the rate of innovation and success in cell and gene therapy with a disruptive capital-efficient model

Investors

20 investors on ElevateBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
F2 Ventures
EcoR1 Capital
Redmile Group
MPM BioImpact
Samsara BioCapital
Series B+ 15 investors entered at this stage
SoftBank
Citadel
Surveyor Capital
EDBI
Matrix Capital Management
Novo Nordisk
ITOCHU
Woodline Partners
Invus
Vestinwolf Financial Holdings
Vertex Ventures HC
Lee Family Office (Asia)
Fidelity Investments
Emerson Collective
Vertex Holdings

Global footprint

Where ElevateBio has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.5%
🇮🇳 India0.3%
2 countries shown
Web traffic by country
50K monthly visits
across markets
🇺🇸 United States90.6%
🇨🇦 Canada3.6%
🇮🇳 India3%
🇬🇧 United Kingdom2%
Top 4 markets shown

Patent intelligence

$18M patent portfolio · 23 active families

Estimated portfolio value
$18M
0.67% of valuation · 6.1× smaller than top peer CRISPR Therapeutics ($107M)
23 active patent families
Where ElevateBio innovates Molecular biologyBioinformaticsSomatostatin receptor 2AgonistImmunology

Where ElevateBio concentrates vs peers

Each axis is a top-10 topic across ElevateBio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

ElevateBio's 3 investments and acquisitions.

Every disclosed deal where ElevateBio appeared as a backer or acquirer, 2021–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across ElevateBio's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where ElevateBio deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        ElevateBio's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Sentiment on X

        What X is saying about ElevateBio

        An AI-synthesized read of the highest-engagement posts about ElevateBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See ElevateBio on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.